Current investigations into Glypican-3, a highly specific antigen in HCC, have demonstrated that BsAbs targeting both Glypican-3 and CD3 can significantly enhance cytotoxic immune responses against tumor cells [105]. The gene discussed is GPC3; the disease is neoplasm.